Search - tctmd.com

Displaying 1 - 20 of 825

Sort: Relevancy | Date

WHO Endorses Treating Obesity in Adults With GLP-1s

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

December 01, 2025

TCTMD’s Top 10 Most Popular Stories for November 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

December 01, 2025

November 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

November 24, 2025

Chronic Pain Linked to Increased Risk for Incident Hypertension

News Daily News

Chronic Pain Linked to Increased Risk for Incident Hypertension

November 20, 2025

Online Calculator Allows Young Adults to See How Their 30-Year CV Risk Compares to Peers’

News Daily News

Online Calculator Allows Young Adults to See How Their 30-Year CV Risk Compares to Peers’

Yael L. Maxwell

November 19, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

November 04, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

October 07, 2025

ACC: It’s Time for Clinicians to Address Inflammation in CVD

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

October 03, 2025

TCTMD’s Top 10 Most Popular Stories for September 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

September 18, 2025

Doctors Skeptical of Their Peers Who Use Generative AI

News Daily News

Doctors Skeptical of Their Peers Who Use Generative AI

September 15, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.